Study results on whether adagrasib (Krazati) needs to be combined with other drugs

Adagrasib (Krazati, generic name: Adagrasib) is a KRAS G12C inhibitor, mainly used to treat patients with KRAS G12Cmutated non-small cell lung cancer (NSCLC) and other malignant tumors. In terms of monotherapy, adagrasib has demonstrated high objective response rates and disease control rates in clinical trials, providing a new treatment option for patients with KRAS mutations that were difficult to target in the past. However, as the treatment time is prolonged, some patients develop drug resistance or decrease in efficacy. Therefore, researchers began to explore the possibility of combining adagrasib with other drugs to extend the duration of efficacy and expand the applicable population.

In terms of combination immunotherapy, the combination of adagrasib and PD-1/PD-L1 immune checkpoint inhibitors has attracted much attention. Some early studies have shown that this type of combination regimen can enhance the immune response and improve the tumor microenvironment in some patients with KRAS G12C mutations, which may improve the treatment response rate and delay the occurrence of drug resistance. Currently, some phase I/II clinical trials are evaluating the safety and efficacy of adagrasiib combined with immunological drugs in NSCLC and other solid tumors. Preliminary results show that the combination regimen is generally well tolerated, but the optimal dosing sequence and population selection need to be further determined.

In addition, the combination of adagrasib and other targeted drugs is also a research hotspot. For example, KRAS mutated tumors are often accompanied by activation of pathways such as EGFR, MET or PI3K, which may lead to resistance to monotherapy. Combining EGFR inhibitors, SHP2 inhibitors or other downstream signaling pathway inhibitors is expected to achieve synergistic inhibition, block multiple signaling pathways, and further improve the efficacy. Some studies have been carried out in the field of colorectal cancer and lung cancer, and early data show that combination therapy shows better disease control rates in patients with complex drug resistance mechanisms.

Overall, the combination treatment of adagrasib and other drugs is an important development direction in the future. Although monotherapy is effective, combination immunotherapy and multi-target combination therapy may be more suitable for long-term disease control and overcoming drug resistance. A number of clinical trials are still ongoing, and future research results will determine the specific positioning and use strategies of the combination regimen in clinical practice. For patients, whether to use combination therapy needs to be based on the type of mutation, disease progression, and individual tolerance. Doctors will develop an individualized plan after comprehensive evaluation.

Reference materials:https://www.drugs.com/